IRIDEX Corporation
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- IRIDEX Corporation (Nasdaq: IRIX), founded in 1989 and headquartered in Mountain View, California, develops, manufactures and markets innovative laser-based medical systems, delivery devices and consumable instrumentation primarily for the ophthalmology market, including treatments for glaucoma, diabetic macular edema and other retinal diseases. The company offers Cyclo G6 glaucoma laser systems and MicroPulse P3 devices; IQ 532, IQ 577 and IQ 810 laser photocoagulators; Iridex 532 and Iridex 577 lasers; EndoProbe handpieces; vitreoretinal consumables; laser delivery probes; and transscleral laser solutions powered by proprietary MicroPulse technology, which enables tissue-sparing procedures. IRIDEX products serve ophthalmologists, hospitals and ambulatory surgery centers in the United States through a direct sales force and internationally in over 100 countries via direct sales and approximately 60 independent distributors. In March 2025, the company secured a $10 million strategic investment from Novel Inspiration International Co., comprising $6 million in Series B Preferred Stock and $4 million in convertible notes with an option for an additional $10 million, to support growth initiatives, repay existing debt and pursue opportunities in laser-based glaucoma treatments following November 2024 regulatory changes limiting competing MIGS devices; IRIDEX also appointed Patrick Mercer as CEO in October 2024 and Romeo Dizon as CFO in March 2025, while launching the Iridex 532 and 577 lasers in January 2024 and advancing clinical studies on MicroPulse technology.
IRIX Stock Up 4% As Q1 Loss Narrows Y/Y on Glaucoma Product Growth
IRIDEX Corporation (IRIX) Q1 2026 Earnings Call Transcript
Iridex Reports First Quarter 2026 Financial Results
Iridex to Report First Quarter 2026 Financial Results on May 19, 2026
Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology
Iridex's Q4 Loss Narrows Year Over Year on Retina Sales Growth
IRIDEX Corporation (IRIX) Q4 2025 Earnings Call Transcript
Iridex Reports Fourth Quarter and Full Year 2025 Financial Results
IRIDEX (IRIX) Projected to Post Earnings on Thursday
Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026
Iridex Announces Plans to Relocate Headquarters
Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025
Zacks Initiates Coverage of Iridex With Neutral Recommendation
Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management
Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment
Iridex to Present at the Sidoti Year-End Virtual Investor Conference
IRIDEX Corporation (IRIX) Q3 2025 Earnings Call Prepared Remarks Transcript
Iridex Reports Third Quarter 2025 Financial Results
Iridex to Report Third Quarter 2025 Financial Results on November 11, 2025
Iridex Corporation Receives Formal Notification of Nasdaq Listing Compliance